Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.68 |
| ▸ | MAPT | P10636 | 7/20 | 0.67 |
| ▸ | LMNA | P02545 | 5/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.61 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | IDE | P14735 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29937693 | 1.00 | ALDH1A1 (0.68) | ALDH1A1MAPTLMNASMN1; SMN2GAA | |
| SCHEMBL6815260 | 0.85 | GAA (0.69) | ALDH1A1MAPTLMNASMN1; SMN2GAA | |
| SCHEMBL3920380 | 0.85 | SLC6A5 (0.86) | ALDH1A1MAPTSMN1; SMN2SLC6A9SLC6A5 | |
| SCHEMBL7800482 | 0.84 | GAA (0.72) | ALDH1A1MAPTLMNASMN1; SMN2GAA | |
| SCHEMBL6811691 | 0.84 | GAA (0.71) | ALDH1A1MAPTLMNASMN1; SMN2GAA | |
| SCHEMBL2061743 | 0.83 | ALDH1A1 (0.66) | ALDH1A1MAPTLMNASMN1; SMN2MEN1 | |
| SCHEMBL1026363 | 0.83 | ALDH1A1 (0.66) | ALDH1A1MAPTLMNASMN1; SMN2MEN1 | |
| SCHEMBL210786 | 0.83 | ALDH1A1 (0.69) | ALDH1A1MAPTLMNASMN1; SMN2KMT2A | |
| SCHEMBL3252577 | 0.83 | ALDH1A1 (0.66) | ALDH1A1MAPTLMNASMN1; SMN2MEN1 | |
| SCHEMBL2388988 | 0.83 | ALDH1A1 (0.66) | ALDH1A1MAPTLMNASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528810-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4367103-B1 | INHIBITORS OF ALPHA-HEMOLYSIN OF STAPHYLOCOCCUS AUREUS | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2025-09-03 | — | — | EP | disclosed |
| US-20250051325-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2025-02-13 | — | — | US | disclosed |
| US-20240376084-A1 | INHIBITORS OF ALPHA-HEMOLYSIN OF STAPHYLOCOCCUS AUREUS | HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH (DE) | 2024-11-14 | — | — | US | disclosed |
| US-12054483-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-08-06 | — | — | US | disclosed |
| EP-4367103-A1 | INHIBITORS OF ALPHA-HEMOLYSIN OF STAPHYLOCOCCUS AUREUS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2024-05-15 | — | — | EP | disclosed |
| CN-115215816-B | Synthesis method of lactam compound | 普济生物科技（台州）有限公司 | 2024-02-02 | — | — | CN | disclosed |
| WO-2023280970-A1 | INHIBITORS OF ALPHA-HEMOLYSIN OF STAPHYLOCOCCUS AUREUS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2023-01-12 | — | — | WO | disclosed |
| WO-2023280970-A1 | INHIBITORS OF ALPHA-HEMOLYSIN OF STAPHYLOCOCCUS AUREUS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2023-01-12 | — | — | WO | disclosed |
| CN-115215816-A | Synthesis method of lactam compound | 普济生物科技（台州）有限公司 | 2022-10-21 | — | — | CN | disclosed |
| US-8158621-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-7825116-B2 | -(2-Aminopyrid-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine; signal transduction cascade inhibitor; Fc receptors for immunoglobulins IgE and IgG antagonist; autoimmune diseases, antiinflammatory agent; rheumatoid arthritis, multiple sclerosis | RIGEL PHARMACEUTICALS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7812029-B1 | such as N4-[(2,2-Dimethyl-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; Glomerulonephritis; rheumatoid arthritis; systemic lupus erythematosis; multiple sclerosis | RIGEL PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7517886-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7476663-B2 | Substituted thiophene carboxamides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-13 | — | — | US | disclosed |
| CN-101014591-A | Novel substituted thiophenecarboxamides, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INT (DE) | 2007-08-08 | — | — | CN | disclosed |
| EP-1747217-A1 | NOVEL SUBSTITUTED THIOPHENECARBOXAMIDES, THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2007-01-31 | — | — | EP | disclosed |
| US-20050277628-A1 | Substituted thiophene carboxamides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-15 | — | — | US | disclosed |
| WO-2005111029-A1 | NOVEL SUBSTITUTED THIOPHENECARBOXAMIDES, THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
| CN-1678321-A | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS INC (US) | 2005-10-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528810-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | CLK3, CLK2, CLK1 | ALDH1A1 3885/4885MAPT 890/4885LMNA 3740/4885 |
| US-20050277628-A1 | Substituted thiophene carboxamides | OTC, SLC22A8, DDC | ALDH1A1 910/4885MAPT 341/4885LMNA 4288/4885 |
| US-20240376084-A1 | INHIBITORS OF ALPHA-HEMOLYSIN OF STAPHYLOCOCCUS AUREUS | SERPINB1, LTA, SERPINC1 | ALDH1A1 3127/4885MAPT 4709/4885LMNA 1232/4885 |
| US-12054483-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | CLK2, CLK1, CLK3 | ALDH1A1 2781/4885MAPT 341/4885LMNA 3111/4885 |
| US-20250051325-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | CLK2, CLK1, CLK3 | ALDH1A1 2781/4885MAPT 341/4885LMNA 3111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.